Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Diagnosis
1018 results:
1. Nephrotoxicity of targeted therapy used to treat lung cancer.
Li Q; Lin J; Hao G; Xie A; Liu S; Tang B
Front Immunol; 2024; 15():1369118. PubMed ID: 39026680
[TBL] [Abstract] [Full Text] [Related]
2. A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an egfr tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.
Yuen CA; Bao S; Kong XT
Biomark Med; 2024; 18(9):431-439. PubMed ID: 39007837
[TBL] [Abstract] [Full Text] [Related]
3. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
Melosky B; Vincent MD; McGuire AL; Brade AM; Chu Q; Cheema P; Martins I; Spicer JD; Snow S; Juergens RA
Int J Cancer; 2024 Sep; 155(6):963-978. PubMed ID: 38900018
[TBL] [Abstract] [Full Text] [Related]
4. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z
Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346
[TBL] [Abstract] [Full Text] [Related]
5. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
[TBL] [Abstract] [Full Text] [Related]
6. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced egfr-mutated NSCLC.
Saw SPL; Low YF; Lai GGY; Chan LL; Wong WKY; Tsui G; Chen OH; Seet AOL; Tan WC; Tan AC; Chan JWK; Teh YL; Tan WL; Ng QS; Ang MK; Kanesvaran R; Lim DWT; Tan DSW; Mok TSK; Li MSC
Lung Cancer; 2024 Jul; 193():107856. PubMed ID: 38889498
[TBL] [Abstract] [Full Text] [Related]
7. [Progress and Discussion of Perioperative Targeted Therapy in Patients
with egfr-mutated Resectable Non-small cell lung cancer].
Song P; Cui Y
Zhongguo Fei Ai Za Zhi; 2024 May; 27(5):383-390. PubMed ID: 38880926
[TBL] [Abstract] [Full Text] [Related]
8. Identification of Potential Biomarkers of egfr Mutation in Pleural Effusion of Non-small cell lung cancer Patients Based on Metabolomics.
Yu J; Xu H; Feng T; Xie T; Shi T
Clin Lab; 2024 Jun; 70(6):. PubMed ID: 38868885
[TBL] [Abstract] [Full Text] [Related]
9. Custom-Designed Probes for the Accurate Determination of Epidermal Growth Factor Receptor Mutations and Their Allelic Configuration.
Li J; Wang C; Zhao S; Qi L; Yu J; Hu X; Chen L; Sun Y; Wang D; Jiang Y; Du Y
Anal Chem; 2024 Jun; 96(24):10056-10063. PubMed ID: 38832555
[TBL] [Abstract] [Full Text] [Related]
10. Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced egfr-Mutant NSCLC Treated with Frontline Osimertinib.
Papazyan T; Denis MG; Sagan C; Raimbourg J; Herbreteau G; Pons-Tostivint E
Target Oncol; 2024 Jul; 19(4):611-621. PubMed ID: 38825654
[TBL] [Abstract] [Full Text] [Related]
11. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in lung cancer.
Park JS; Park HY; Choi Y
Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
[TBL] [Abstract] [Full Text] [Related]
12. Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.
Lim JU; Kim K; Kim KY; Kang HS; Shin AY; Yeo CD; Kim SK; Park CK; Lee SH; Kim SJ
Thorac Cancer; 2024 Jul; 15(19):1513-1521. PubMed ID: 38798190
[TBL] [Abstract] [Full Text] [Related]
13. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
de Jager VD; Cajiao Garcia BN; Kuijpers CCHJ; de Bock GH; Maas WJ; Timens W; van Kempen LC; van der Wekken AJ; Schuuring E; Willems SM
Eur J Cancer; 2024 Jul; 205():114125. PubMed ID: 38788285
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and predictive value of interstitial lung abnormalities and egfr mutation status in patients with non-small cell lung cancer.
Xu X; Zhu M; Wang Z; Li J; Ouyang T; Chen C; Huang K; Zhang Y; Gao YL
Cancer Imaging; 2024 May; 24(1):66. PubMed ID: 38783331
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of drug resistance for egfr-TKIs in lung cancer via multicellular lung-on-a-chip.
Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450
[TBL] [Abstract] [Full Text] [Related]
16. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting egfr mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract] [Full Text] [Related]
17. Microfluidics-based egfr mutation detection and its implication in the resource-limited clinical setting.
Joshi P; Gogte P; Pai T; Gurav M; Dhanawade D; Karnik N; Deshpande G; Kaushal R; Shetty O
Int J Exp Pathol; 2024 Jun; 105(3):90-99. PubMed ID: 38717047
[TBL] [Abstract] [Full Text] [Related]
18. Completion of Pembrolizumab in Advanced Non-small cell lung cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
Fantoni A; Warburton L; Solomon B; Alexander M; Maddula M; Brown LJ; da Silva IP; Nagrial A; Abu Al-Hial F; Itchins M; Pavlakis N; Bowyer S
Clin Lung Cancer; 2024 Jul; 25(5):449-459. PubMed ID: 38705835
[TBL] [Abstract] [Full Text] [Related]
19. Gold Nanoprobes for Detection of a Crucial egfr Deletion for Early diagnosis of Non-small-cell lung cancer.
Enea M; Nuekaew A; Franco R; Pereira E
Biosensors (Basel); 2024 Mar; 14(4):. PubMed ID: 38667155
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
[Next]
